Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Issue 10387 (6th May 2023)

Record Type:
Journal Article
Title:
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Issue 10387 (6th May 2023)
Main Title:
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Authors:
Abani, Obbina
Abbas, Ali
Abbas, Fatima
Abbas, Joshua
Abbas, Kasim
Abbas, Mustafa
Abbasi, Sadia
Abbass, Hakam
Abbott, Alfie
Abbott, Alison
Abdallah, Nabeel
Abdelaziz, Ammar
Abdelaziz, Ashraf
Abdelfattah, Mohamed
Abdelqader, Bushra
Abdul, Audrey
Abdul, Basir
Abdul, Siddiqui
Abdul Rasheed, Althaf
Abdulakeem, Ajibode
Abdul-Kadir, Rezan
Abdullah, Abdullah
Abdulmumeen, Abdulfatahi
Abdul-Raheem, Rasheed
Abdulshukkoor, Niyaz
Abdusamad, Kula
Abed El Khaleq, Yazeed
Abedalla, Mai
Abeer Ul Amna, Abeer
Abel, Lynn
… (more)
Abstract:
Summary: Background: Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group. Methods: This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting adult patients with clinical evidence of hypoxia (ie, receiving oxygen or with oxygen saturation <92% on room air) were randomly allocated (1:1) to either usual care with higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg dexamethasone once daily for 5 days or until discharge if sooner) or usual standard of care alone (which included dexamethasone 6 mg once daily for 10 days or until discharge if sooner). The primary outcome was 28-day mortality among all randomised participants. On May 11, 2022, the independent data monitoring committee recommended stopping recruitment of patients receiving no oxygen or simple oxygen only due to safety concerns. We report the results for these participants only. Recruitment of patients receiving ventilatory support is ongoing. The RECOVERY trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936 ). Findings: Between May 25, … (more)
Is Part Of:
Lancet. Volume 401:Issue 10387(2023)
Journal:
Lancet
Issue:
Volume 401:Issue 10387(2023)
Issue Display:
Volume 401, Issue 10387 (2023)
Year:
2023
Volume:
401
Issue:
10387
Issue Sort Value:
2023-0401-10387-0000
Page Start:
1499
Page End:
1507
Publication Date:
2023-05-06
Subjects:
Medicine -- Periodicals
Medicine -- Periodicals
Medicine
Medicine
Electronic journals
Periodicals
610.5
Journal URLs:
http://www.thelancet.com/ ↗
http://www.sciencedirect.com/science/journal/01406736 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/S0140-6736(23)00510-X ↗
Languages:
English
ISSNs:
0140-6736
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 5146.000000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
27077.xml